Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 7:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,590 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Major Depressive Disorder \(MDD Clear all
Completed Phase 3 Interventional Results available

A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.

NCT00775203
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Trazodone Hydrochloride (HCl) Extended-Release Tablets, Placebo
Drug
Lead sponsor
Labopharm Inc.
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
28
States / cities
Birmingham, Alabama • Mesa, Arizona • Beverly Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2012 · Synced Sep 24, 2026, 7:50 PM EDT
Recruiting Not applicable Interventional

Behavioral Health Collaborative Care Model in Post-ICU Clinic Family Pilot

NCT07390786
View directory record Official record
Conditions
Critical Illness Recovery, Behavioral Health Concerns, Anxiety, Depression - Major Depressive Disorder, PTSD, Critical Care, Intensive Care, PICS-F
Interventions
Behavioral Treatment
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 24, 2026, 7:50 PM EDT
Completed Not applicable Interventional

Storytelling Video Intervention for Depressed Primary Care Patients - Open Trial

NCT02309060
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Storytelling Video Intervention (sTVi)
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Pawtucket, Rhode Island • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Sep 24, 2026, 7:50 PM EDT
Enrolling by invitation Not applicable Interventional

Resonant Frequency rTMS: A Novel Approach to Target Circuit Modulation in Major Depressive Disorder

NCT06572683
View directory record Official record
Conditions
MDD, Depression
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 24, 2026, 7:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Ketamine for Depression: An MRI Study

NCT02544607
View directory record Official record
Conditions
Depression, Anxious Depression, Major Depressive Disorder
Interventions
Ketamine, Magnetic Resonance Imaging (MRI)
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 24, 2026, 7:50 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

NCT06524830
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
VLS-01-203 BU, VLS-01-BU Placebo
Drug
Lead sponsor
atai Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
34
States / cities
Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 24, 2026, 7:50 PM EDT
Completed Phase 4 Interventional Results available

Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits

NCT04352101
View directory record Official record
Conditions
Major Depression
Interventions
Bupropion XL, Escitalopram
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Sep 24, 2026, 7:50 PM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment

NCT02013609
View directory record Official record
Conditions
MDD
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 35 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
24
States / cities
Cerritos, California • Costa Mesa, California • Garden Grove, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Sep 24, 2026, 7:50 PM EDT
Completed Phase 3 Interventional

The Effects and Mechanisms of Mindfulness Based Cognitive Therapy (MBCT) on Depressive Symptoms and Depression Relapse

NCT01145872
View directory record Official record
Conditions
Major Depressive Disorder, Recurrent
Interventions
Mindfulness Based Cognitive Therapy, Health Enhancement Program
Behavioral
Lead sponsor
University of Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 24, 2026, 7:50 PM EDT
Completed No phase listed Observational

A Longitudinal Study of Inflammatory Pathways in Depression

NCT04159207
View directory record Official record
Conditions
Major Depressive Disorder, Suicide, Attempted
Interventions
Not listed
Lead sponsor
Van Andel Research Institute
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 24, 2026, 7:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.

NCT01243957
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Fluoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Sep 24, 2026, 7:50 PM EDT
Completed Phase 4 Interventional Results available

Does Dual Therapy Hasten Antidepressant Response?

NCT00519428
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
escitalopram, bupropion extra long (XL), escitalopram + bupropion
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Sep 24, 2026, 7:50 PM EDT
Recruiting Not applicable Interventional

Evaluating tDCS Brain-stimulation in Depression Using MRI

NCT05598034
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Left DLPFC tDCS, Right DLPFC tDCS, Cognitive task
Device · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
20 Years to 55 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 24, 2026, 7:50 PM EDT
Completed Phase 2Phase 3 Interventional

Effects of Duloxetine vs. Escitalopram on Heart Rate Variability in Depression

NCT00215228
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
duloxetine vs. escitalopram
Drug
Lead sponsor
Duke University
Other
Eligibility
20 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 20, 2014 · Synced Sep 24, 2026, 7:50 PM EDT
Completed Phase 1 Interventional

A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode

NCT07549581
View directory record Official record
Conditions
Schizophrenia, Major Depressive Disorder (MDD), Bipolar Disorder
Interventions
SEP-380135, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 24, 2026, 7:50 PM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms

NCT02013531
View directory record Official record
Conditions
Major Depressive Disorder, Anxiety
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
21
States / cities
Tuscon, Arizona • Garden Grove, California • Oceanside, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Sep 24, 2026, 7:50 PM EDT
Terminated Phase 4 Interventional Results available

Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine

NCT02969876
View directory record Official record
Conditions
Depressive Disorder, Major Depression, Depression, Depression, Unipolar
Interventions
Vortioxetine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2019 · Synced Sep 24, 2026, 7:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Antepartum Study on Use of Interpersonal Psychotherapy at 3 New York City Site

NCT00251043
View directory record Official record
Conditions
Depression
Interventions
Interpersonal psychotherapy for depression in pregnancy, Parenting education program (PEP)
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2012 · Synced Sep 24, 2026, 7:50 PM EDT
Completed Phase 2 Interventional

ALTO-300 in Depression

NCT05118750
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALTO-300 oral (PO) tablet
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 74 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Culver City, California • Sacramento, California • Santee, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Sep 24, 2026, 7:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2216684 in Healthy Participants

NCT01380691
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo-matching LY2216684, Placebo-matching alcoholic beverage, Alcoholic beverage
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Sep 24, 2026, 7:50 PM EDT
Completed Phase 4 Interventional Results available

Brain Aging and Treatment Response in Geriatric Depression

NCT01902004
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Depression
Interventions
Escitalopram, Memantine, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 24, 2026, 7:50 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Study of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder

NCT00529789
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
duloxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
7 Years to 17 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
22
States / cities
Dothan, Alabama • Chandler, Arizona • El Centro, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2011 · Synced Sep 24, 2026, 7:50 PM EDT
Terminated Phase 3 Interventional Results available

A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)

NCT03610048
View directory record Official record
Conditions
Refractory Major Depressive Disorder
Interventions
ALKS 5461
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 72 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
29
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Alamitos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 24, 2026, 7:50 PM EDT
Completed Not applicable Interventional

Clinical Trials of Three Non-Drug Treatments for Winter Depression (SAD)

NCT00006517
View directory record Official record
Conditions
Seasonal Affective Disorder, Mood Disorders, Depression
Interventions
bright light box, dawn simulator, high-output negative ion generator, low-output negative ion generator, dawn light pulse
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 24, 2026, 7:50 PM EDT